These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 3512191)

  • 41. Biologic studies on chemically synthesized pentasaccharide and tetrasaccharide fragments.
    Choay J
    Semin Thromb Hemost; 1985 Apr; 11(2):81-5. PubMed ID: 4035368
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A comparison of the antithrombotic and haemorrhagic effects of a low molecular weight heparin (LHN-1) and conventional heparin.
    Diness V; Nielsen JI; Pedersen PC; Wolffbrandt KH; Ostergaard PB
    Thromb Haemost; 1986 Jun; 55(3):410-4. PubMed ID: 3750271
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacological and clinical studies with Lomoparan, a low molecular weight glycosaminoglycan.
    Nurmohamed MT; Fareed J; Hoppensteadt D; Walenga JM; ten Cate JW
    Semin Thromb Hemost; 1991; 17 Suppl 2():205-13. PubMed ID: 1948091
    [No Abstract]   [Full Text] [Related]  

  • 44. Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments.
    Fareed J; Walenga JM; Williamson K; Emanuele RM; Kumar A; Hoppensteadt DA
    Semin Thromb Hemost; 1985 Jan; 11(1):56-74. PubMed ID: 3883500
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-thrombotic effect of a synthetic heparin mimetic in an arterial model of thrombosis in rats: comparison with unfractionated heparin and nadroparin.
    Leger P; Cambus JP; Herault JP; Herbert JM; Boneu B
    Thromb Haemost; 2002 Oct; 88(4):687-8. PubMed ID: 12362245
    [No Abstract]   [Full Text] [Related]  

  • 46. Antithrombotic drugs: part I.
    Gallus AS; Hirsh J
    Drugs; 1976; 12(1):41-68. PubMed ID: 789043
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of heparin and heparinlike molecules in thrombosis and atherosclerosis.
    Rosenberg RD
    Fed Proc; 1985 Feb; 44(2):404-9. PubMed ID: 3155697
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The new heparins].
    Samama M
    Presse Med; 1986 Sep; 15(32):1631-5. PubMed ID: 2949211
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Physiologic properties of heparin--thromboplastin complex].
    Kudriashov BA; Liapina LA
    Fiziol Zh SSSR Im I M Sechenova; 1978 Jun; 64(6):771-6. PubMed ID: 680264
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Antithrombotic effect of acetylsalicylic acid, heparin and phenprocoumon on the formation of experimental coagulation thrombi].
    Zimmermann R; Barth P; Masche R
    Verh Dtsch Ges Inn Med; 1974; 80():1446-8. PubMed ID: 4454451
    [No Abstract]   [Full Text] [Related]  

  • 51. Influence of molecular weight of chemically sulfated citrus pectin fractions on their antithrombotic and bleeding effects.
    Cipriani TR; Gracher AH; de Souza LM; Fonseca RJ; Belmiro CL; Gorin PA; Sassaki GL; Iacomini M
    Thromb Haemost; 2009 May; 101(5):860-6. PubMed ID: 19404539
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Natural and therapeutic regulation on blood coagulation].
    Fukutake K
    Nihon Rinsho; 1989 Apr; 47(4):732-8. PubMed ID: 2746883
    [No Abstract]   [Full Text] [Related]  

  • 53. An investigation of the functional role of the carboxylic groups of heparin. Affinity for antithrombin III and anti-Xa activity of selectively carboxyl esterified heparin.
    Mardiguian J; Trillou M
    Semin Thromb Hemost; 1985 Jan; 11(1):34-6. PubMed ID: 3975640
    [No Abstract]   [Full Text] [Related]  

  • 54. Antithrombin activity of a polyelectrolyte synthesized from cis-1,4-polyisoprene.
    Beugeling T; Van Der Does L; Bantjes A; Sederel WL
    J Biomed Mater Res; 1974 Nov; 8(6):375-9. PubMed ID: 4436339
    [No Abstract]   [Full Text] [Related]  

  • 55. [Basic principles anticoagulant therapy].
    Mammen EF
    Internist (Berl); 1969 Jan; 10(1):2-8. PubMed ID: 4190310
    [No Abstract]   [Full Text] [Related]  

  • 56. Antithrombotic properties in rabbits of heparin and heparin fragments covalently coupled to human antithrombin III.
    Mattsson C; Hoylaerts M; Holmer E; Uthne T; Collen D
    J Clin Invest; 1985 Apr; 75(4):1169-73. PubMed ID: 3988937
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins? Biochemical considerations.
    Ostergaard P; Nordfang O; Petersen LC; Valentin S; Kristensen H
    Haemostasis; 1993 Mar; 23 Suppl 1():107-11. PubMed ID: 8388348
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tissue distribution and antithrombotic activity of unlabeled or 14C-labeled porcine intestinal mucosal heparin following administration to rats by the oral route.
    Hiebert LM; Wice SM; Ping T; Hileman RE; Capila I; Linhardt RJ
    Can J Physiol Pharmacol; 2000 Apr; 78(4):307-20. PubMed ID: 10772058
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Glycosaminoglycan backbone is not required for the modulation of hemostasis: effect of different heparin derivatives and non-glycosaminoglycan analogs.
    Bouças RI; Jarrouge-Bouças TR; Lima MA; Trindade ES; Moraes FA; Cavalheiro RP; Tersariol IL; Hoppenstead D; Fareed J; Nader HB
    Matrix Biol; 2012 Jun; 31(5):308-16. PubMed ID: 22504459
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antithrombin-mediated inhibition of factor VIIa-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site to antithrombin.
    Lormeau JC; Herault JP; Herbert JM
    Thromb Haemost; 1996 Jul; 76(1):5-8. PubMed ID: 8819242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.